Leonid Kotkin
Urology · Brighton, MANPI 1326035825
Payments from drug & device makers
Across 110 payments — averaging $54.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gyrus ACMI, Inc.$3K
- Olympus Medical Systems Corporation$2K
- Dentsply IH Inc.$422
- Astellas Pharma US Inc$360
- Therapeuticsmd, Inc.$147
- Neotract Inc.$117
- plus $665 from 18 others
What the payments were for
- Consulting fees$4,32072%
- Food & beverage$1,59526%
- Education$1162%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gyrus ACMI, Inc. | 2 | $2,700 |
| Olympus Medical Systems Corporation | 1 | $1,620 |
| Dentsply IH Inc. | 37 | $422 |
| Astellas Pharma US Inc | 22 | $360 |
| Therapeuticsmd, Inc. | 10 | $147 |
| Neotract Inc. | 6 | $117 |
| Antares Pharma, Inc. | 5 | $108 |
| Pfizer | 6 | $94 |
| AbbVie(2 entities) | 3 | $66 |
| Teleflex LLC | 2 | $60 |
| Johnson & Johnson | 2 | $46 |
| Tolmar Pharmaceuticals, Inc. | 2 | $38 |
| Merck | 1 | $31 |
| Bard Access Systems, Inc. | 1 | $27 |
| Rochester Medical Corporation | 1 | $24 |
| Medtronic | 1 | $24 |
| Urovant Sciences Inc | 1 | $21 |
| Coloplast | 1 | $20 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Blue Earth Diagnostics | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Soltive$2,700
- OES CHOLEDOCHOFIBERSCOPE$1,620
How this compares
$6,031 in reported general payments places this provider in the 70th percentile of 327 urology providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 36 | $16,304 |
| Tamsulosin Hcl | 98 | $1,435 |
| Dutasteride | 21 | $1,345 |
| Finasteride | 96 | $1,238 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $569 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $412 |
| Doxazosin Mesylate | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $360 | $16,30436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 327 urology providers in Massachusetts.
Other urology in Brighton
- David StaskinBrighton$807K
- Jairam EswaraBrighton$64K
- Christopher CutieBoston$3.5M
- Henry MitchesonWatertown$1.6M
- Brian EisnerBoston$1.4M
- Mark PrestonBoston$1.2M
- Abraham MorgentalerChestnut Hill$522K
- Alejandro SanchezBoston$349K
- Liam HurleyNorth Andover$319K
- Adam KibelBoston$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.